NYU Langone and Dana-Farber Co-Develop Solavia Decision Suite, a Next-Generation Oncology Clinical Decision Support Platform
核心洞察
NYU Langone Health and Dana-Farber Cancer Institute have co-developed Solavia Decision Suite (搜索), an oncology clinical decision support platform that launched internally on June 30 and is now commercially available.
The platform integrates directly into the electronic health record, providing oncologists with seamless access to the latest evidence, biomarkers, guidelines, and therapeutic options at the point of care.
The collaboration emerged after Philips sunset its oncology pathways business, prompting the two institutions to build a more robust, scalable, and workflow-integrated solution rather than adopt an existing vendor product.
NYU Langone Health and Dana-Farber Cancer Institute have formed a strategic collaboration to co-develop Solavia Decision Suite (搜索), a next-generation oncology support platform designed to improve cancer (搜索) care for patients and clinicians alike. The platform launched internally at NYU Langone on June 30 and is now commercially available to other health systems — a rare move for hospitals, which typically keep digital tools in-house or purchase them from software vendors.
Embedded directly in the electronic health record (EHR), Solavia provides physicians with seamless access to the latest evidence, biomarkers, guidelines, and therapeutic options, enabling them to align patient data with a body of relevant clinical research and make treatment decisions accordingly.
"For oncologists to decide which chemotherapy a patient receives is a complex matter because oncology research changes quite a bit," said Nader Mherabi, executive vice president, vice dean, and chief digital and information officer at NYU Langone.
From Users to Developers: The Origin of Solavia
The collaboration traces back to a shared experience: both institutions previously used an oncology pathways product from Philips, with the clinical content curated by Dana-Farber. When Philips decided to sunset its oncology business, NYU Langone and Dana-Farber faced a choice — find a new vendor or partner to build something more robust.
"Dana-Farber came with a lot of oncology informatics and content, and then they found that NYU Langone is advanced in terms of product development and product lifecycle. So that synergy was there," Mherabi explained. "We knew what the pitfalls and pain points of the other product were, and we had good insights into what we could build that would really please our oncologists and be great for patient care."
The decision to build rather than buy was driven by several factors. First, the institutions wanted a tool that could be highly integrated into the clinician workflow within the EHR — both NYU Langone and Dana-Farber use Epic, though Solavia can integrate with other systems such as Cerner or function as a standalone application. Second, they prioritized ease of use given the complexity of oncology pathways, which involve multinested branches to identify the best treatment for each patient. Third, they sought a cloud-based, scalable architecture that would be "highly functional and extendable."
Clinical Impact and Workflow Integration
Solavia is expected to strengthen care standardization, reduce unnecessary variation in care delivery, and improve the way care pathways are managed. The platform reflects real-world workflows, evolving oncology evidence, and the needs of multidisciplinary cancer (搜索) care teams.
"As oncologists, we know that cancer (搜索) therapy evolves quickly, and keeping clinicians current on the latest evidence relevant to each patient can save time and support the best possible care," said John P. Leonard, MD, division chief of hematology and medical oncology and chief clinical officer at NYU Langone's Perlmutter Cancer Center. "Solavia is an exciting step toward making that expertise more accessible in real time and helping care teams navigate complex treatment decisions."
David Jackman, MD, medical director of clinical pathways and new business initiatives at Dana-Farber, added: "Solavia is designed with clinicians in mind and patients at the center. The platform is intended to support care teams with evidence-based, context-aware guidance that helps make cancer (搜索) treatment more personalized, coordinated, and consistent."
Governance and Commercialization Strategy
The two nonprofits have established a governance board and formal agreements between the parties, with legal, compliance, and ventures teams engaged to ensure the platform supports not only NYU Langone and Dana-Farber but also future adopting institutions. Solavia is designed to be multitenant, with each institution's data separately handled and subjected to rigorous security reviews.
Commercialization is being led by NYU Langone's Technology Opportunities and Ventures arm, which serves as the primary point of contact for health systems interested in adoption. Any future proceeds from broader platform licensing will be reinvested in improvements to Solavia, with the aim of advancing care across the oncology community.
Broader Implications for Healthcare Technology Development
The Solavia collaboration reflects a broader strategic vision at both institutions: moving from being users of digital tools to helping build the future of oncology care. The initiative also supports NYU Langone's and Dana-Farber's broader goals in precision medicine and digital innovation, two critical aspects of the learning health system model.
Mherabi noted that the economics of enterprise software are increasingly driving health systems to consider building their own solutions. "Institutions often buy a big stack of software where they use maybe 30% of the software but they're still paying for 100%," he said. "Also, with the advances of amazing technology, cloud-based capabilities and AI, the timeline for product development and building something that specifically solves a problem has matured."
By co-developing Solavia, both institutions are building internal capabilities in product governance, pathway digitization, implementation science, and clinical transformation — expertise that could benefit oncology and potentially other service lines in the future.